Literature DB >> 19815499

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.

Noa Stanietsky1, Hrvoje Simic, Jurica Arapovic, Amir Toporik, Ofer Levy, Amit Novik, Zurit Levine, Meirav Beiman, Liat Dassa, Hagit Achdout, Noam Stern-Ginossar, Pinhas Tsukerman, Stipan Jonjic, Ofer Mandelboim.   

Abstract

NK cell cytotoxicity is controlled by numerous NK inhibitory and activating receptors. Most of the inhibitory receptors bind MHC class I proteins and are expressed in a variegated fashion. It was recently shown that TIGIT, a new protein expressed by T and NK cells binds to PVR and PVR-like receptors and inhibits T cell activity indirectly through the manipulation of DC activity. Here, we show that TIGIT is expressed by all human NK cells, that it binds PVR and PVRL2 but not PVRL3 and that it inhibits NK cytotoxicity directly through its ITIM. Finally, we show that TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19815499      PMCID: PMC2764881          DOI: 10.1073/pnas.0903474106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

Review 1.  Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

Authors:  R H Schwartz
Journal:  Cell       Date:  1992-12-24       Impact factor: 41.582

2.  Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules.

Authors:  R Biassoni; A Pessino; A Malaspina; C Cantoni; C Bottino; S Sivori; L Moretta; A Moretta
Journal:  Eur J Immunol       Date:  1997-12       Impact factor: 5.532

3.  A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling.

Authors:  T Muta; T Kurosaki; Z Misulovin; M Sanchez; M C Nussenzweig; J V Ravetch
Journal:  Nature       Date:  1994-05-26       Impact factor: 49.962

4.  B70 antigen is a second ligand for CTLA-4 and CD28.

Authors:  M Azuma; D Ito; H Yagita; K Okumura; J H Phillips; L L Lanier; C Somoza
Journal:  Nature       Date:  1993-11-04       Impact factor: 49.962

5.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

Authors:  G J Freeman; J G Gribben; V A Boussiotis; J W Ng; V A Restivo; L A Lombard; G S Gray; L M Nadler
Journal:  Science       Date:  1993-11-05       Impact factor: 47.728

6.  Poliovirus receptor on human blood cells: a possible extraneural site of poliovirus replication.

Authors:  M S Freistadt; H B Fleit; E Wimmer
Journal:  Virology       Date:  1993-08       Impact factor: 3.616

7.  A new member of the immunoglobulin superfamily--CTLA-4.

Authors:  J F Brunet; F Denizot; M F Luciani; M Roux-Dosseto; M Suzan; M G Mattei; P Golstein
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

8.  CTLA-4 is a second receptor for the B cell activation antigen B7.

Authors:  P S Linsley; W Brady; M Urnes; L S Grosmaire; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

9.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.

Authors:  Cameron S Brandt; Myriam Baratin; Eugene C Yi; Jacob Kennedy; Zeren Gao; Brian Fox; Betty Haldeman; Craig D Ostrander; Tomonori Kaifu; Christian Chabannon; Alessandro Moretta; Robert West; Wenfeng Xu; Eric Vivier; Steven D Levin
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

10.  The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions.

Authors:  R Biassoni; C Cantoni; M Falco; S Verdiani; C Bottino; M Vitale; R Conte; A Poggi; A Moretta; L Moretta
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

View more
  282 in total

1.  IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors:  Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2020-06-26       Impact factor: 12.531

Review 2.  Cell surface signaling molecules in the control of immune responses: a tide model.

Authors:  Yuwen Zhu; Sheng Yao; Lieping Chen
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

3.  Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering.

Authors:  Katharina F Stengel; Kristin Harden-Bowles; Xin Yu; Lionel Rouge; Jianping Yin; Laëtitia Comps-Agrar; Christian Wiesmann; J Fernando Bazan; Dan L Eaton; Jane L Grogan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-15       Impact factor: 11.205

Review 4.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

5.  The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR.

Authors:  Giulia Matusali; Marina Potestà; Angela Santoni; Cristina Cerboni; Margherita Doria
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

6.  T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Authors:  Sarah E Josefsson; Kanutte Huse; Arne Kolstad; Klaus Beiske; Daniela Pende; Chloé B Steen; Else Marit Inderberg; Ole Christian Lingjærde; Bjørn Østenstad; Erlend B Smeland; Ronald Levy; Jonathan M Irish; June H Myklebust
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

7.  NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy.

Authors:  Yotam Bar-On; Yoav Charpak-Amikam; Ariella Glasner; Batya Isaacson; Alexandra Duev-Cohen; Pinchas Tsukerman; Alexander Varvak; Michal Mandelboim; Ofer Mandelboim
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 8.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

9.  T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.

Authors:  Man Li; Pengyan Xia; Ying Du; Shengwu Liu; Guanling Huang; Jun Chen; Honglian Zhang; Ning Hou; Xuan Cheng; Luyu Zhou; Peifeng Li; Xiao Yang; Zusen Fan
Journal:  J Biol Chem       Date:  2014-05-09       Impact factor: 5.157

Review 10.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.